期刊文献+

利奈唑胺致血小板减少3例 被引量:7

下载PDF
导出
出处 《医药导报》 CAS 2010年第6期811-812,共2页 Herald of Medicine
  • 相关文献

参考文献5

二级参考文献27

  • 1DIEKENA DI, JONES RN. Oxazolidinones: a review [ J ]. Drugs, 2000,59( 1 ) :7 - 16.
  • 2MOELLERING RC JR. Linezolid:the first oxazolidinone antimicrobial[ J], Ann Intern Med,2003,138(2) :135 - 142.
  • 3MEAGHER AK, FORREST A, RAYNER CA, et al. Population pharmacoklnetics of linezalid in patients treated in a compassionate-use program [ J ]. Antimicrob Agents Chemother, 2003,47 ( 2 ) : 548 - 553.
  • 4JANKOWSKI A, STEFANI KW. Linezolid-novel antibiotic for the treatment of gram-positive bacterial infections [ J ]. Wiad Lek, 2006,59(9/10) :727 -731.
  • 5RICHARD G, WUNDERINK MD, JORDI RELLO,et al. Linezolid vs Vancomycin. Analysis of two double-blinded studies of patients with methicillin-resistant staphylococcus aureus nosocomial pneumonia[ J ]. Chest,2003,124 ( 5 ) : 1789 - 1797.
  • 6ZEANA C, KUBIN C J, LA-LATTA P,et al. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid :case report and review of the literature[ J]. Clin Infect Dis, 2001,33 ( 15 ) :477 - 482.
  • 7AMENT PW, JAMSHED N, HOME JP. Linezolid : its role in the treatment of gram-positive,drug-resistant bacterial infections[ J ]. Am Fam Physician ,2002,65 (4) :663 - 670,
  • 8HAMEL JC, STAPERT D, MOERMAN JK, et al. Linezolid, critical characterstics[ J]. Infection,2000,28 ( 1 ) :60 - 64.
  • 9STALKER DJ,JUNGBLUTH GL. Clinical pharmacokinetics of linezolld, a novel oxazolidinone antlbacterial [ J ]. Clin Pharrnacokinet,2003,42 ( 13 ) : 1129 - 1140.
  • 10SCHROEDER TH ,HANSEN M, STEPHAN M ,et al. Elimination of linezolid by an in vitro extracorporeal circuit mode [ J ]. Int J Artif Organs ,2004,27 ( 6 )473 - 479.

共引文献111

同被引文献65

  • 1杨秀丽 袁雍.利奈唑胺与头孢哌酮舒巴坦合用致血小板减少1例.药学与临床杂志,2009,4(16):20-20.
  • 2杨曦 朱曼 孙艳 等.利奈唑胺致血小板减少1例.中国药品申请与监测杂志,2008,9(24):127-128.
  • 3Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram- positive bacterial infections: meta-a- nalysis of randomised controlled trials [J ]. Lancet Infect Dis, 2008, 8 (1) : 53-66.
  • 4Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skinstruc- ture infections and catheter-related bloodstream infections : noninferiority of linezolid in a phase 3 study [ J ]. Clin Infect Dis, 2009, 48 (2) : 203 -212.
  • 5Bernstein W B, Trotta R F, Rector J T, et al. Mechanisms for linezolid induced anemia and thrombocytopenia [J]. Ann Pharmacother, 2003, 37(4): 517-520.
  • 6MoelleringRC JR. Linezolid: the first oxzolidinone antimicrobial [ J ]. Ann Intern Med,2003,138(2) :135 - 142.
  • 7Diekena DI, Jones RN. Oxazolidinones : a revew [ J ]. Drugs, 2000, 59(1) :7 -16.
  • 8Rubinsteine, Isturizr, Standifordhc, et al. Worldwide assessment of linezolid "s clinical safety and tolerability: comparator-controlled phase Ⅲ studies [ J ]. Antimicrob Agents Chemother, 2003,47 (6) : 1824 - 1831.
  • 9ernstein WB, Trottarf, Rectorj T, et al. Mechanisms for linezolid-in- duced anemia and thrombocytopenia [ J ]. Ann Pharmacother, 2003, 37(4) :517 -515.
  • 10Wiener M, Guo Y, Pate 1 G, et al. Lactic ac idosis after treatment with linezolid [ J]. Infecti on ,2007,35 (4) :278 - 281.

引证文献7

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部